Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 3
Author: ICICI Securities Limited

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 10% YoY to | 587 crore (I-direct estimate: | 553 crore) mainly due to 15% growth in export formulations, led by 79% growth in the Asia business to | 161 crore and ~20% growth in the US to | 71 crore. Domestic sales grew 4% YoY to | 155 crore EBITDA margins improved 36 bps YoY to 33.6% (I-direct estimate: 33.5%) mainly due to an improvement in gross margins by 123 bps YoY to 81.3%. EBITDA increased 11% YoY to | 198 crore...